Pretax income is the income that a company earns before paying income taxes. Xeris Biopharma Holdings's pretax income for the
three
months ended in Sep. 2024 was $-19.1 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-65.6 Mil.
Xeris Biopharma Holdings's pretax margin was -35.13%.
During the past 8 years, Xeris Biopharma Holdings's highest Pretax Margin was -35.02%. The lowest was -4630.35%. And the median was -837.64%.
Xeris Biopharma Holdings Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Xeris Biopharma Holdings's Pre-Tax Income
For the Biotechnology subindustry, Xeris Biopharma Holdings's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's Pre-Tax Income falls into.
Xeris Biopharma Holdings Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Xeris Biopharma Holdings's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-65.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings (NAS:XERS) Pre-Tax Income Explanation
Xeris Biopharma Holdings's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as
During the past 8 years, Xeris Biopharma Holdings's highest Pretax Margin was -35.02%. The lowest was -4630.35%. And the median was -837.64%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XERS has been successfully added to your 